澳洲无计划停用阿斯利康新冠疫苗 泰国总理今早成功接种
澳洲未有计划停止接种阿斯利康新冠疫苗,较早时德国、法国、意大利及西班牙等国家停止使用阿斯利康疫苗,因收到疫苗或会引起血栓塞的报告。
澳洲首席医学官Paul Kelly称,欧洲药物管理局正在调查事件,澳洲政府对疫苗仍然充满信心,因为目前尚无证据表明疫苗会引起血栓塞。
泰国总理巴育今日接种阿斯利康新冠疫苗,巴育及其内阁原先在上周五注射疫苗,但其後泰国暂停接种,因忧虑阿斯利康疫苗或会引起血栓塞问题。
本月将年满67岁的巴育表示,注射後感觉良好,希望能提高公众信心。泰国卫生部长表示,在许多国家表示该疫苗未有产生血栓塞问题後,将恢复接种计划。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.